On May 13, the White House announced the latest big science initiative: a pledge of a half billion dollars to study microbes in humans, crops, soils, oceans and more. This initiative — which includes $121 million in Federal funding over two years — builds on the NIH Human Microbiome Project, begun in 2007, as well...
On May 18, the U.S. Food and Drug Administration approved the latest immunotherapeutic drug, atezolizumab (Tecentriq), from Roche’s California division, Genentech. The drug, a PD-L1 inhibitor, is the first product in its class to gain approval for a common form of bladder cancer, urothelial carcinoma — specifically for patients with advanced disease or those who...